Plain-English translation of NCT07025629 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called dapagliflozin to see if it can protect your heart and kidneys after you leave the intensive care unit (ICU). You'll take one tablet daily for one year, and researchers will check your heart and kidney health through regular visits and blood tests to compare how the medication works against a placebo (a pill with no active ingredient).
People who have been critically ill in the ICU often develop heart and kidney problems afterward. This medication is already used for certain conditions, and researchers want to know if it can help prevent or slow heart and kidney damage in ICU survivors.
You likely qualify if…
You likely don't qualify if…
You'll visit the hospital at the start, then at 6 months and 1 year for check-ups that include blood tests and heart/kidney assessments. You'll also receive two brief phone calls at 3 and 9 months. Throughout the year, you'll take one tablet by mouth each day — either the active medication or a placebo. After the 1-year treatment period ends, there's one final hospital visit 6 weeks later to check your health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France